Literature DB >> 20195187

Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.

Zana Ahmad1, Carrie Maiorana Brown, Andrew K Patel, Allen F Ryan, Rutherford Ongkeko, Joni K Doherty.   

Abstract

HYPOTHESIS: To investigate the early events in molecular progression toward schwannoma tumorigenesis, we developed an in vitro model of human Schwann cell tumorigenesis by merlin knockdown.
BACKGROUND: Neurofibromatosis 2 (NF2)-related and sporadic vestibular schwannoma (VS) exhibit loss of functional merlin (schwannomin). After loss of merlin expression in the Schwann cell, the initial steps toward VS tumorigenesis are unknown. Merlin, a putative tumor suppressor protein, interacts with many cellular proteins, regulating their function. Among these are receptor tyrosine kinases, including the epidermal growth factor receptor family B (ErbB) family receptors epidermal growth factor receptor and ErbB2. Functional merlin interacts with and internalizes these growth factor receptors, silencing their proliferation and survival signaling. Deregulation of CD44, the cell adhesion/signaling molecule and cancer stem cell marker, has also been implicated in VS tumorigenesis.
METHODS: Merlin knockdown was performed using small interfering RNA transfection into human Schwann cell primary cultures. Knockdown was confirmed by real-time quantitative PCR, immunofluorescence, and Western analysis. Expression profiles of ErbB, merlin, and the stem cell markers nestin and CD44 were examined in knockdowns. Proliferation rate was assessed with bromodeoxyuridine incorporation, and radiation sensitivity was assessed using the Annexin assay in knockdowns versus controls.
RESULTS: Merlin knockdowns demonstrated increased proliferation rate, upregulation of epidermal growth factor receptor, ErbB2, and ErbB3, CD44, and nestin. Short-term merlin depletion had no effect on gamma irradiation sensitivity compared with controls.
CONCLUSION: Merlin depletion results in deregulation of ErbB receptor signaling, promotes a dedifferentiated state, and increases Schwann cell proliferation, suggesting critical steps toward schwannoma tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20195187      PMCID: PMC2873969          DOI: 10.1097/MAO.0b013e3181d2777f

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  19 in total

1.  The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44.

Authors:  H Morrison; L S Sherman; J Legg; F Banine; C Isacke; C A Haipek; D H Gutmann; H Ponta; P Herrlich
Journal:  Genes Dev       Date:  2001-04-15       Impact factor: 11.361

2.  Arrested neural and advanced mesenchymal differentiation of glioblastoma cells-comparative study with neural progenitors.

Authors:  Piotr Rieske; Ewa Golanska; Magdalena Zakrzewska; Sylwester Piaskowski; Krystyna Hulas-Bigoszewska; Magdalena Wolańczyk; Malgorzata Szybka; Monika Witusik-Perkowska; Dariusz J Jaskolski; Krzysztof Zakrzewski; Wojciech Biernat; Barbara Krynska; Pawel P Liberski
Journal:  BMC Cancer       Date:  2009-02-14       Impact factor: 4.430

Review 3.  Cancer stem cells in nervous system tumors.

Authors:  Sheila K Singh; Ian D Clarke; Takuichiro Hide; Peter B Dirks
Journal:  Oncogene       Date:  2004-09-20       Impact factor: 9.867

4.  Effects of ErbB2 signaling on the response of vestibular schwannoma cells to gamma-irradiation.

Authors:  Marlan R Hansen; J Jason Clark; Bruce J Gantz; Prabhat C Goswami
Journal:  Laryngoscope       Date:  2008-06       Impact factor: 3.325

5.  Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology.

Authors:  Cristina Fernandez-Valle; Yong Tang; Jerome Ricard; Alma Rodenas-Ruano; Anna Taylor; Elizabeth Hackler; John Biggerstaff; Jared Iacovelli
Journal:  Nat Genet       Date:  2002-07-15       Impact factor: 38.330

6.  The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.

Authors:  J Jason Clark; Matthew Provenzano; Henry R Diggelmann; Ningyong Xu; Skylar S Hansen; Marlan R Hansen
Journal:  Otol Neurotol       Date:  2008-09       Impact factor: 2.311

7.  ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy.

Authors:  Joni K Doherty; Weg Ongkeko; Brianna Crawley; Ali Andalibi; Allen F Ryan
Journal:  Otol Neurotol       Date:  2008-01       Impact factor: 2.311

8.  Phosphatidylinositol 3-kinase/AKT pathway activation in human vestibular schwannoma.

Authors:  Abraham Jacob; Tina X Lee; Brian A Neff; Shyra Miller; Bradley Welling; Long-Sheng Chang
Journal:  Otol Neurotol       Date:  2008-01       Impact factor: 2.311

9.  Expression of neuregulin and activation of erbB receptors in vestibular schwannomas: possible autocrine loop stimulation.

Authors:  Marlan R Hansen; Fred H Linthicum
Journal:  Otol Neurotol       Date:  2004-03       Impact factor: 2.311

10.  Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas.

Authors:  D Lallemand; J Manent; A Couvelard; A Watilliaux; M Siena; F Chareyre; A Lampin; M Niwa-Kawakita; M Kalamarides; M Giovannini
Journal:  Oncogene       Date:  2008-11-24       Impact factor: 9.867

View more
  11 in total

1.  Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.

Authors:  Kristy Truong; Iram Ahmad; J Jason Clark; Alison Seline; Tyler Bertroche; Brian Mostaert; Douglas J Van Daele; Marlan R Hansen
Journal:  Neuroscience       Date:  2018-02-03       Impact factor: 3.590

2.  The role of NF2 gene mutations and pathogenesis-related proteins in sporadic vestibular schwannomas in young individuals.

Authors:  Hongsai Chen; Xiaoman Zhang; Zhihua Zhang; Tao Yang; Zhaoyan Wang; Hao Wu
Journal:  Mol Cell Biochem       Date:  2014-03-12       Impact factor: 3.396

3.  Identification of novel fusion transcripts in meningioma.

Authors:  A Basit Khan; Ron Gadot; Arya Shetty; James C Bayley; Caroline C Hadley; Maria F Cardenas; Ali Jalali; Akdes S Harmanci; Arif O Harmanci; David A Wheeler; Tiemo J Klisch; Akash J Patel
Journal:  J Neurooncol       Date:  2020-09-19       Impact factor: 4.130

4.  p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB.

Authors:  Iram Ahmad; Wei Ying Yue; Augusta Fernando; J Jason Clark; Erika A Woodson; Marlan R Hansen
Journal:  Glia       Date:  2014-06-26       Impact factor: 7.452

5.  Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas.

Authors:  Ryota Tamura; Yukina Morimoto; Mizuto Sato; Yuki Kuranari; Yumiko Oishi; Kenzo Kosugi; Kazunari Yoshida; Masahiro Toda
Journal:  J Neurooncol       Date:  2020-01-03       Impact factor: 4.130

6.  Fourth ventricular schwannoma: identical clinicopathologic features as schwann cell-derived schwannoma with unique etiopathologic origins.

Authors:  Tiffany R Hodges; Isaac O Karikari; Shahid M Nimjee; June Tibaleka; Thomas J Cummings; Senthil Radhakrishnan; Allan H Friedman
Journal:  Case Rep Med       Date:  2011-12-13

Review 7.  Role of Merlin/NF2 inactivation in tumor biology.

Authors:  A M Petrilli; C Fernández-Valle
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

8.  Differential NF2 Gene Status in Sporadic Vestibular Schwannomas and its Prognostic Impact on Tumour Growth Patterns.

Authors:  Hongsai Chen; Lu Xue; Hantao Wang; Zhaoyan Wang; Hao Wu
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

9.  p53 performs an essential role in mediating the oncogenic stimulus triggered by loss of expression of neurofibromatosis type 2 during in vitro tumor progression.

Authors:  Xiye Li; Hongsai Chen; Lu Xue; Xiuhong Pang; Xiaoman Zhang; Zhengjie Zhu; Weidong Zhu; Zhaoyan Wang; Hao Wu
Journal:  Oncol Lett       Date:  2017-06-21       Impact factor: 2.967

Review 10.  Neurovascular patterning cues and implications for central and peripheral neurological disease.

Authors:  Nicholas T Gamboa; Philipp Taussky; Min S Park; William T Couldwell; Mark A Mahan; M Yashar S Kalani
Journal:  Surg Neurol Int       Date:  2017-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.